Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy

Leonela Amoasii, John C.W. Hildyard, Hui Li, Efrain Sanchez-Ortiz, Alex Mireault, Daniel Caballero, Rachel Harron, Thaleia Rengina Stathopoulou, Claire Massey, John M. Shelton, Rhonda Bassel-Duby, Richard J. Piercy, Eric N. Olson

Research output: Contribution to journalArticlepeer-review

158 Scopus citations

Abstract

Mutations in the gene encoding dystrophin, a protein that maintains muscle integrity and function, cause Duchenne muscular dystrophy (DMD). The deltaE50-MD dog model of DMD harbors a mutation corresponding to a mutational "hotspot" in the human DMD gene. We used adeno-associated viruses to deliver CRISPR gene editing components to four dogs and examined dystrophin protein expression 6 weeks after intramuscular delivery (n = 2) or 8 weeks after systemic delivery (n = 2). After systemic delivery in skeletal muscle, dystrophin was restored to levels ranging from 3 to 90% of normal, depending on muscle type. In cardiac muscle, dystrophin levels in the dog receiving the highest dose reached 92% of normal. The treated dogs also showed improved muscle histology. These large-animal data support the concept that, with further development, gene editing approaches may prove clinically useful for the treatment of DMD.

Original languageEnglish (US)
Pages (from-to)86-91
Number of pages6
JournalScience
Volume362
Issue number6410
DOIs
StatePublished - Oct 5 2018

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this